Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study

Peter Novak, Daniela Arantxa Pimentel Maldonado, Vera Novak, Peter Novak, Daniela Arantxa Pimentel Maldonado, Vera Novak

Abstract

Parkinson disease (PD) is associated with cognitive impairment. We aimed to determine the effects of intranasal insulin (INI) on cognition and motor performance in PD. This was a proof of concept, randomized, double-blinded, placebo-controlled trial evaluating the effects of 40 international units (IU) of insulin or saline once daily for four weeks on cognitive and functional performance. Of 16 subjects enrolled, eight in the INI group and six in the placebo group completed verbal fluency (FAS), Unified Parkinson Disease Scale (UPDRS), and modified Hoehn and Yahr scale (HY, PD severity) at baseline and post-treatment and were included in the analyses. After treatment, the INI group had a better total FAS score (p = 0.02) (41 ± 8.2 vs. 30.8 ± 7.1, mean ±SD, p = 0.02) compared to the placebo group. The INI group also had improved HY (p = 0.04) and UPDRS-Motor (Part III) (p = 0.02) scores when compared to baseline. One INI treated patient with multiple system atrophy (MSA) remained stable and did not show disease progression. The placebo group had no change. INI administration was well tolerated and there were no hypoglycemic episodes or serious study related adverse events or medications interactions. INI is safe in PD and MSA patients and may provide clinically relevant functional improvement. Larger studies are warranted to determine the INI effect in treatment of cognitive and motor impairment in Parkinson disease. Trial Registration: ClinicalTrial.gov NCT02064166.

Conflict of interest statement

No competing interests.

Figures

Fig 1. Study flow diagram.
Fig 1. Study flow diagram.

References

    1. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord Off J Mov Disord Soc. 2011;26: 1814–1824. 10.1002/mds.23823
    1. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord Off J Mov Disord Soc. 2006;21: 1343–1349. 10.1002/mds.20974
    1. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord Off J Mov Disord Soc. 2012;27: 349–356. 10.1002/mds.24893
    1. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75: 1062–1069. 10.1212/WNL.0b013e3181f39d0e
    1. Coelho M, Marti MJ, Sampaio C, Ferreira JJ, Valldeoriola F, Rosa MM, et al. Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson’s disease: the Barcelona-Lisbon cohort. Eur J Neurol. 2015;22: 305–312. 10.1111/ene.12567
    1. Lucas-Jiménez O, Díez-Cirarda M, Ojedaa N, Peña J, Cabrera-Zubizarreta A, Ibarretxe-Bilbao N. Verbal Memory in Parkinson’s Disease: A Combined DTI and fMRI Study. J Park Dis. 2015;5: 793–804.
    1. Lucas-Jiménez O, Ojeda N, Peña J, Díez-Cirarda M, Cabrera-Zubizarreta A, Gómez-Esteban JC, et al. Altered functional connectivity in the default mode network is associated with cognitive impairment and brain anatomical changes in Parkinson’s disease. Parkinsonism Relat Disord. 2016;33: 58–64. 10.1016/j.parkreldis.2016.09.012
    1. Amboni M, Tessitore A, Esposito F, Santangelo G, Picillo M, Vitale C, et al. Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease. J Neurol. 2015;262: 425–434. 10.1007/s00415-014-7591-5
    1. Disbrow EA, Carmichael O, He J, Lanni KE, Dressler EM, Zhang L, et al. Resting state functional connectivity is associated with cognitive dysfunction in non-demented people with Parkinson’s disease. J Park Dis. 2014;4: 453–465. 10.3233/JPD-130341
    1. Melzer TR, Watts R, MacAskill MR, Pearson JF, Rüeger S, Pitcher TL, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease. Brain J Neurol. 2011;134: 845–855. 10.1093/brain/awq377
    1. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, et al. White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology. 2013;80: 1841–1849. 10.1212/WNL.0b013e3182929f62
    1. Tessitore A, Esposito F, Vitale C, Santangelo G, Amboni M, Russo A, et al. Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease. Neurology. 2012;79: 2226–2232. 10.1212/WNL.0b013e31827689d6
    1. Baggio H-C, Sala-Llonch R, Segura B, Marti M-J, Valldeoriola F, Compta Y, et al. Functional brain networks and cognitive deficits in Parkinson’s disease. Hum Brain Mapp. 2014;35: 4620–4634. 10.1002/hbm.22499
    1. Bezdicek O, Ballarini T, Růžička F, Roth J, Mueller K, Jech R, et al. Mild cognitive impairment disrupts attention network connectivity in Parkinson’s disease: A combined multimodal MRI and meta-analytical study. Neuropsychologia. 2018;112: 105–115. 10.1016/j.neuropsychologia.2018.03.011
    1. Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait speed and survival in older adults. JAMA. 2011;305: 50–58. 10.1001/jama.2010.1923
    1. O’Shea S, Morris ME, Iansek R. Dual task interference during gait in people with Parkinson disease: effects of motor versus cognitive secondary tasks. Phys Ther. 2002;82: 888–897.
    1. Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab. 2012;97: 366–376. 10.1210/jc.2011-1802
    1. Zhang H, Hao Y, Manor B, Novak P, Milberg W, Zhang J, et al. Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes. Diabetes. 2015;64: 1025–1034. 10.2337/db14-1000
    1. Novak V, Milberg W, Hao Y, Munshi M, Novak P, Galica A, et al. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care. 2014;37: 751–759. 10.2337/dc13-1672
    1. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis JAD. 2008;13: 323–331.
    1. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69: 29–38. 10.1001/archneurol.2011.233
    1. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53: 695–699. 10.1111/j.1532-5415.2005.53221.x
    1. Yeudall LT, Reddon JR, Gill DM, Stefanyk WO. Normative data for the Halstead-Reitan neuropsychological tests stratified by age and sex. J Clin Psychol. 1987;43: 346–367.
    1. Whisman MA, Judd CM, Whiteford NT, Gelhorn HL. Measurement invariance of the Beck Depression Inventory-Second Edition (BDI-II) across gender, race, and ethnicity in college students. Assessment. 2013;20: 419–428. 10.1177/1073191112460273
    1. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord Off J Mov Disord Soc. 2004;19: 1020–1028. 10.1002/mds.20213
    1. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40: 1529–1534.
    1. Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarriés J, Bermejo F. Unified Parkinson’s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord Off J Mov Disord Soc. 1994;9: 76–83. 10.1002/mds.870090112
    1. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson’s Disease Rating Scale motor examination. Mov Disord Off J Mov Disord Soc. 1994;9: 89–91. 10.1002/mds.870090114
    1. van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ. Motor patterns in Parkinson’s disease: a data-driven approach. Mov Disord Off J Mov Disord Soc. 2009;24: 1042–1047. 10.1002/mds.22512
    1. Maggio M, Ceda GP, Ticinesi A, De Vita F, Gelmini G, Costantino C, et al. Instrumental and Non-Instrumental Evaluation of 4-Meter Walking Speed in Older Individuals. PloS One. 2016;11: e0153583 10.1371/journal.pone.0153583
    1. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol Off J Natl Acad Neuropsychol. 1999;14: 167–177.
    1. Schmid V, Kullmann S, Gfrörer W, Hund V, Hallschmid M, Lipp H-P, et al. Safety of intranasal human insulin: A review. Diabetes Obes Metab. 2018;20: 1563–1577. 10.1111/dom.13279
    1. Iodice V, Low DA, Vichayanrat E, Mathias CJ. Cardiovascular autonomic dysfunction in MSA and Parkinson’s disease: similarities and differences. J Neurol Sci. 2011;310: 133–138. 10.1016/j.jns.2011.07.014

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren